What it is.
Calcium alpha-ketoglutarate presented as a planned single-ingredient capsule with source-linked research context.
Ca-AKG is a defined ingredient. Nutrae keeps its planned capsule specification separate from external ingredient research.
What researchers measured.
Human studies of calcium alpha-ketoglutarate use differing formulations, doses, populations and designs. No completed study tests the planned Nutrae capsule.
Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen in postmenopausal women with osteopenia: six-month study
Design: Randomized, double-blind, parallel-group trial · 76 postmenopausal women with osteopenia
Form, dose and duration: Calcium alpha-ketoglutarate compared with calcium alone · Approximately 6 g/day alpha-ketoglutarate plus 1.68 g/day calcium · 6 months
Reported result: CTX decreased, including a reported 37% reduction at 24 weeks. Bone mineral density increased from baseline, but the between-group difference was not statistically significant.
Important limit: The alpha-ketoglutarate dose was substantially higher than Nutrae's planned per-capsule amount, and the population and outcome differ from the intended general-wellness use.
Primary recordAlpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults: protocol for the ABLE randomized controlled trial
Design: Randomized, placebo-controlled trial protocol; results not posted · Planned 120 adults aged 40 to 60 years
Form, dose and duration: Sustained-release calcium alpha-ketoglutarate · 1,000 mg/day · 6 months plus 3 months of follow-up
Reported result: The registry lists the trial as active, not recruiting, with estimated completion in January 2027. No results were publicly posted as of 2026-07-18.
Important limit: A protocol cannot support an efficacy claim. Recruitment status and completion dates can change, and the sustained-release study product does not automatically match Nutrae's planned capsule.
Primary recordEvaluation of the Efficacy of Calcium alpha-Ketoglutarate (AKG-Ca) in Improving Human Aging
Design: Randomized, quadruple-masked, placebo-controlled registered trial; results not posted · Adults enrolled in a registered clinical study
Form, dose and duration: Calcium alpha-ketoglutarate · 2,000 mg/day · 12 weeks
Reported result: No results were publicly posted in the trial registry as of 2026-07-18.
Important limit: Registry information is not an efficacy result, and its dose and release profile cannot determine Nutrae's final directions.
Primary recordWhat this does not prove.
Ingredient research does not establish an outcome for the finished Nutrae capsule. The final product specification and label will control at release.
No finished Nutrae product has been tested in a randomized human trial. Ingredient studies do not establish an outcome for this capsule or show that it produces the same exposure as another formulation.
Use the final label.
Long-term supplemental safety data in healthy adults remain limited. Ca-AKG also contributes calcium, so total calcium intake and individual medical context matter.
- Human studies use different doses and populations and do not establish long-term safety.
- People with kidney or calcium-balance conditions, medicine use or planned surgery should seek qualified medical advice.